Related Experiment Video

Updated: Jun 6, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines

Anne Cooley1, Stanislav Zelivianski, Jacqueline S Jeruss

  • 1Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Cell Cycle (Georgetown, Tex.)
|December 15, 2010
PubMed

Insights

Cyclin E overexpression in breast cancer inhibits the tumor suppressor Smad3 via CDK2 phosphorylation. Inhibiting CDK2 may restore Smad3 activity, offering a potential treatment for aggressive breast cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Smad3, a TGFβ pathway component, induces G1 arrest in breast cancer.
  • Cyclin E overexpression correlates with poor breast cancer prognosis.
  • Cyclin E/CDK2 can phosphorylate and inhibit Smad3 activity.

Purpose of the Study:

  • To investigate if CDK2 phosphorylation of Smad3 mediates cyclin E's inhibition of Smad3's tumor suppressor function.
  • To explore the therapeutic potential of targeting CDK2 in cyclin E-overexpressing breast cancers.

Main Methods:

  • Co-transfection of MCF7 cells (parental, vector control, or cyclin E overexpressing) with Smad3 constructs (wild type or phosphorylation-site mutants) and a Smad3-responsive reporter.
  • Luciferase reporter assays and mRNA analysis to assess Smad3 function.
  • Evaluation of Cdk2 inhibitor and cdk2 siRNA effects on Smad3 activity.

Main Results:

  • Smad3 mutants with altered CDK phosphorylation sites showed increased p15/p21 mRNA, decreased c-myc mRNA, and enhanced reporter activity.
  • Cdk2 inhibition (siRNA or chemical inhibitor) significantly increased Smad3-responsive reporter activity.
  • These findings confirm CDK2-mediated phosphorylation of Smad3 by cyclin E.

Conclusions:

  • Cyclin E inhibits Smad3 tumor suppressor activity through CDK2-dependent phosphorylation in MCF7 cells.
  • Targeting CDK2 may restore Smad3 function in breast cancer.
  • CDK2 inhibition presents a potential therapeutic strategy for cyclin E-overexpressing breast cancers.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...